New Antibody Armanezumab May Be Possible Therapeutic Strategy for ALS – ALS News Today
ALS News Today |
New Antibody Armanezumab May Be Possible Therapeutic Strategy for ALS
ALS News Today “We are still at the early stages of immunotherapy for neurodegenerative disorders and the field is advancing methodically. Humanized monoclonal antibodies have become very effective in treating various cancers, and we hope that disorders of the brain … |
|
Trial aims to extend remission for children treated with T-cell immunotherapy for leukemia
Medical Xpress After phase 1 results of Seattle Children’s Pediatric Leukemia Adoptive Therapy (PLAT-02) trial have shown T-cell immunotherapy to be effective in getting 93 percent of patients with relapsed or refractory acute lymphoblastic leukemia (ALL) into … |
|
Trial aims to extend remission for children treated with T–cell immunotherapy for leukemia
EurekAlert (press release) The new phase 1 pilot study, PLAT-03, will examine the feasibility and safety of administering a second T-cell product intended to increase the long-term persistence of the patient’s chimeric antigen receptor (CAR) T cells that were reprogrammed to … |
|
Trial aims to extend remission for children treated with T–cell immunotherapy for leukemia
EurekAlert (press release) The new phase 1 pilot study, PLAT-03, will examine the feasibility and safety of administering a second T-cell product intended to increase the long-term persistence of the patient’s chimeric antigen receptor (CAR) T cells that were reprogrammed to … |
Medscape |
Avelumab: Another Immunotherapy for Bladder Cancer
Medscape Another immunotherapy has been approved for use in urothelial cancer, the most common type of bladder cancer, in the United States. Avelumab (Bavencio, EMD Serono INc), which is a programmed cell death ligand–1 (PD L1) inhibitor, has been approved … Avelumab Granted Accelerated Approval for Bladder CancerSpecialty Pharmacy Times |